Localization of Deep Brain Stimulation Contacts Using Corticospinal/Corticobulbar Tracts Stimulation

BackgroundSuccessful deep brain stimulation (DBS) in Parkinson’s disease (PD) requires optimal electrode placement. One technique of intraoperative electrode testing is determination of stimulation thresholds inducing corticospinal/corticobulbar tracts (CSBT) motor contractions.ObjectiveThis study aims to analyze correlations between DBS electrode distance to CSBT and contraction thresholds, with either visual or electromyography (EMG) detection, to establish an intraoperative tool devoted to ensure safe distance of the electrode to the CSBT.MethodsTwelve PD patients with subthalamic nucleus DBS participated. Thresholds of muscular contractions were assessed clinically and with EMG, for three different sets of stimulation parameters, all monopolar: 130 Hz high-frequency stimulation (HFS); 2 Hz low-frequency stimulation with either 60 or 210 µs (LFS-60, LFS-210). The anatomical distance of electrode contacts to CSBT was measured from fused CT-MRI.ResultsThe best linear correlation was found for thresholds of visually detected contractions with HFS (r2 = 0.63, p < 0.0001) when estimated stimulation currents rather than voltages were used. This correlation was found in agreement with an accepted model of electrical spatial extent of activation (r2 = 0.50). When using LFS, the correlation found remained lower than for HFS but increased when EMG was used. Indeed, the detection of contraction thresholds with EMG versus visual inspection did allow more frequent detection of face contractions, contributing to improve that correlation.ConclusionThe correlation between electrode distance to the CSBT and contraction thresholds was found better when estimated with currents rather than voltage, eliminating the variance due to electrode impedance. Using LFS did not improve the precision of that evaluation, but EMG did. This technique provides a prediction band to ensure minimum distance of the electrode contacts to the CSBT, integrating the variance that can be encountered between prediction of models and practice

"De mandibulae dysarthria"--thinking outside the box

Urgent decisions in the Emergency Department allow for only a short history and physical examination

Deep Brain Stimulation Improves Parkinson’s Disease-Associated Pain by Decreasing Spinal Nociception

Dopamine exerts antinociceptive effects on pain in PD at cortical and spinal levels, whereas only cortical effects have been described for DBS, so far. By assessing the nociceptive flexion reflex (NFR) threshold at medication on, and DBS ON and OFF in two patients, we showed that DBS additionally decreases spinal nociception

Modeling of Electric Fields in Individual Imaging Atlas for Capsular Threshold Prediction of Deep Brain Stimulation in Parkinson's Disease: A Pilot Study.

Background: Modeling of deep brain stimulation electric fields and anatomy-based software might improve post-operative management of patients with Parkinson's disease (PD) who have benefitted from subthalamic nucleus deep brain stimulation (STN-DBS). Objective: We compared clinical and software-guided determination of the thresholds for current diffusion to the pyramidal tract, the most frequent limiting side effect in post-operative management of STN-DBS PD patients. Methods: We assessed monopolar reviews in 16 consecutive STN-DBS PD patients and retrospectively compared clinical capsular thresholds, which had been assessed according to standard clinical practice, to those predicted by volume of tissue activated (VTA) model software. All the modeling steps were performed blinded from patients' clinical evaluations. Results: At the group level, we found a significant correlation (p = 0.0001) when performing statistical analysis on the z-scored capsular thresholds, but with a low regression coefficient (r = 0.2445). When considering intra-patient analysis, we found significant correlations (p < 0.05) between capsular threshold as modeled with the software and capsular threshold as determined clinically in five patients (31.2%). Conclusions: In this pilot study, the VTA model software was of limited assistance in identifying capsular thresholds for the whole cohort due to a large inter-patient variability. Clinical testing remains the gold standard in selecting stimulation parameters for STN-DBS in PD

Consensus Statement on High-Intensity Focused Ultrasound for Functional Neurosurgery in Switzerland.

Background: Magnetic resonance-guided high-intensity focused ultrasound (MRgHiFUS) has evolved into a viable ablative treatment option for functional neurosurgery. However, it is not clear yet, how this new technology should be integrated into current and established clinical practice and a consensus should be found about recommended indications, stereotactic targets, patient selection, and outcome measurements. Objective: To sum up and unify current knowledge and clinical experience of Swiss neurological and neurosurgical communities regarding MRgHiFUS interventions for brain disorders to be published as a national consensus paper. Methods: Eighteen experienced neurosurgeons and neurologists practicing in Switzerland in the field of movement disorders and one health physicist representing 15 departments of 12 Swiss clinical centers and 5 medical societies participated in the workshop and contributed to the consensus paper. All experts have experience with current treatment modalities or with MRgHiFUS. They were invited to participate in two workshops and consensus meetings and one online meeting. As part of workshop preparations, a thorough literature review was undertaken and distributed among participants together with a list of relevant discussion topics. Special emphasis was put on current experience and practice, and areas of controversy regarding clinical application of MRgHiFUS for functional neurosurgery. Results: The recommendations addressed lesioning for treatment of brain disorders in general, and with respect to MRgHiFUS indications, stereotactic targets, treatment alternatives, patient selection and management, standardization of reporting and follow-up, and initialization of a national registry for interventional therapies of movement disorders. Good clinical evidence is presently only available for unilateral thalamic lesioning in treating essential tremor or tremor-dominant Parkinson's disease and, to a minor extent, for unilateral subthalamotomy for Parkinson's disease motor features. However, the workgroup unequivocally recommends further exploration and adaptation of MRgHiFUS-based functional lesioning interventions and confirms the need for outcome-based evaluation of these approaches based on a unified registry. MRgHiFUS and DBS should be evaluated by experts familiar with both methods, as they are mutually complementing therapy options to be appreciated for their distinct advantages and potential. Conclusion: This multidisciplinary consensus paper is a representative current recommendation for safe implementation and standardized practice of MRgHiFUS treatments for functional neurosurgery in Switzerland

A spinal cord neuroprosthesis for locomotor deficits due to Parkinson’s disease

International audiencePeople with late-stage Parkinson’s disease (PD) often suffer from debilitating locomotor deficits that are resistant to currently available therapies. To alleviate these deficits, we developed a neuroprosthesis operating in closed loop that targets the dorsal root entry zones innervating lumbosacral segments to reproduce the natural spatiotemporal activation of the lumbosacral spinal cord during walking. We first developed this neuroprosthesis in a non-human primate model that replicates locomotor deficits due to PD. This neuroprosthesis not only alleviated locomotor deficits but also restored skilled walking in this model. We then implanted the neuroprosthesis in a 62-year-old male with a 30-year history of PD who presented with severe gait impairments and frequent falls that were medically refractory to currently available therapies. We found that the neuroprosthesis interacted synergistically with deep brain stimulation of the subthalamic nucleus and dopaminergic replacement therapies to alleviate asymmetry and promote longer steps, improve balance and reduce freezing of gait. This neuroprosthesis opens new perspectives to reduce the severity of locomotor deficits in people with PD